Glaritus Use In Pregnancy & Lactation

Pregnancy: There are no well-controlled clinical studies of the use of Glaritus in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. All pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. It is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. In patients with diabetes or gestational diabetes, insulin requirements may decrease during the first trimester, generally increase during the second trimester, and rapidly decline after delivery. Careful monitoring of glucose control is essential in these patients. Therefore, female patients should be advised to tell their physicians if they intend to become, or if they become pregnant while taking Glaritus.
Insulin requirements may decrease during the first trimester and generally increase during the second and third trimesters.
Nursing Mothers: Endogenous insulin is present in human milk; it is unknown whether insulin glargine is excreted in human milk. Because many drugs, including human insulin, are excreted in human milk, caution should be exercised when Glaritus is administered to a nursing woman. Use of Glaritus is compatible with breastfeeding, but women with diabetes who are lactating may require adjustments of their insulin doses.